Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers

Figure 1 Treatment responses. A: End of treatment (ETR) and sustained virological response at week 12 (SVR12) in prior treatment failures (non-responders [partial and null responders] and relapsers or miscellaneous), and in all patients; B: Undetectable HCV RNA at week 4, 8 and 12 in non-responders, relapsers, treatment naïve and miscellaneous and overall patients groups; C: ETR and SVR rates in Asians vs Caucasians in prior relapsers (Asian = 51; Caucasians = 28) and non-responders (Asian = 32; Caucasians = 20). Only significant differences are shown.